Who
Paul Streck
EVP, Head of R&D
Company insider
Files Form 4 as: EVP, Head of R&D, PepGen; Chief Medical Officer, Albireo Pharma; Chief Medical Officer, Alder Biopharmaceuticals; Chief Medical Officer, Insmed.
In numbers
- Trades disclosed
- 30
- Buys
- 1
- Sells
- 1
- Bought
- $10K
- Sold
- $23K
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 5 Jun 2017
- Last trade
- 4 Mar 2026
- Last filed
- 6 Mar 2026
Companies traded
Activity over time
1 May 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Mar 2026filed 6 Mar 2026 | PEPG PepGenBiotechnology | SEC FORM 4 Sold | $11K1,832 at $6.23 | filing |
| 4 Mar 2026filed 6 Mar 2026 | PEPG PepGenBiotechnology | SEC FORM 4 Sold | $29647 at $6.29 | filing |
| 4 Mar 2026filed 6 Mar 2026 | PEPG PepGenBiotechnology | SEC FORM 4 Sold | $11K1,832 at $6.23 | filing |
| 4 Mar 2026filed 6 Mar 2026 | PEPG PepGenBiotechnology | SEC FORM 4 Sold | $29647 at $6.29 | filing |
| 1 Mar 2026filed 2 Mar 2026 | PEPG PepGenBiotechnology | SEC FORM 4 Code A | —50,300 at $0.00 | filing |
| 1 Mar 2026filed 2 Mar 2026 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —196,500 at $0.00 | filing |
| 1 Mar 2026filed 2 Mar 2026 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —196,500 at $0.00 | filing |
| 1 Mar 2026filed 2 Mar 2026 | PEPG PepGenBiotechnology | SEC FORM 4 Code A | —50,300 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code D | —202,816 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —202,816 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 at $0.00 | filing |
| 4 Nov 2025filed 18 Dec 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | PEPG PepGenBiotechnology | SEC FORM 4 Bought | $10K8,375 at $1.24 | filing |
| 3 Mar 2025filed 5 Mar 2025 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,000 at $0.00 | filing |
| 3 Mar 2025filed 5 Mar 2025 | PEPG PepGenBiotechnology | SEC FORM 4 Code A | —19,430 at $0.00 | filing |
| 19 Aug 2024filed 20 Aug 2024 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —202,816 at $0.00 | filing |
| 19 Aug 2024filed 20 Aug 2024 | PEPG PepGenoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Mar 2023filed 2 Mar 2023 | Albireo Pharmaoption or derivative | SEC FORM 4 Code D | —118,966 | filing |
| 19 Jan 2023filed 27 Jan 2023 | Albireo Pharma | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 19 Jan 2023filed 25 Jan 2023 | Albireo Pharma | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.